iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement
January 15, 2014 08:31 ET | iBio, Inc.
NEWARK, DE--(Marketwired - Jan 15, 2014) -  iBio, Inc. (NYSE MKT: IBIO) announced today that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer...
iBio Appoints Senior Management for New Business Unit, iBio Brazil
November 05, 2013 14:59 ET | iBio, Inc.
NEWARK, DE--(Marketwired - Nov 5, 2013) - iBio, Inc. (NYSE MKT: IBIO), has appointed Carlos Picosse as chief executive officer and Dr. Renato Lobo as chief medical officer of iBio Brazil, a...
iBio to Present at the 2013 Gateway Conference on September 10
September 05, 2013 08:30 ET | iBio, Inc.
SAN FRANCISCO, CA--(Marketwired - Sep 5, 2013) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of technology for both proprietary and biosimilar products for use in development and production of...